BUZZ-Outlook Therapeutics 因 FDA 第三次驳回眼科药物申请而暴跌

路透中文

Jan 02

BUZZ-Outlook <a href="https://laohu8.com/S/LENZ">Therapeutics</a> 因 FDA 第三次驳回眼科药物申请而暴跌

1月2日 - ** Outlook Therapeutics OTLK.O股价盘前大跌59.6%，至64美分

** 美国 FDA 拒绝批准 (link) 公司的 Lytenava 用于治疗湿性年龄相关性黄斑变性，理由是缺乏确证疗效的证据

** 该决定是继 2023 年和 2025 年 8 月拒绝批准后的第三次拒绝。

** Lytenava是贝伐珠单抗针对眼部疾病的改良药物，在关键试验中未能与罗氏ROG.S的Lucentis相媲美

** 该药物已在欧盟和英国获得批准；FDA尚未说明可接受哪种类型的确证证据

** 2025年OTLK下跌16.4

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2600507340"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2600507340\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2600507340?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-02 19:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600507340","market":"hk","top_or_hot":-1,"title":"BUZZ-Outlook Therapeutics 因 FDA 第三次驳回眼科药物申请而暴跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 因 FDA 第三次驳回眼科药物申请而暴跌</title></head><body><p>\n<span>1月2日</span><span> - </span>** Outlook Therapeutics <span>OTLK.O</span>股价盘前大跌59.6%，至64美分 </p><p>** 美国 FDA 拒绝批准 (<span>link</span>) 公司的 Lytenava 用于治疗湿性年龄相关性黄斑变性，理由是缺乏确证疗效的证据</p><p>** 该决定是继 2023 年和 2025 年 8 月拒绝批准后的第三次拒绝。</p><p>** Lytenava是贝伐珠单抗针对眼部疾病的改良药物，在关键试验中未能与罗氏<span>ROG.S</span>的Lucentis相媲美</p><p>** 该药物已在欧盟和英国获得批准；FDA尚未说明可接受哪种类型的确证证据</p><p>** 2025年OTLK下跌16.4 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Outlook Therapeutics 因 FDA 第三次驳回眼科药物申请而暴跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Outlook Therapeutics 因 FDA 第三次驳回眼科药物申请而暴跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-01-02 19:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> 因 FDA 第三次驳回眼科药物申请而暴跌</title></head><body><p>\n<span>1月2日</span><span> - </span>** Outlook Therapeutics <span>OTLK.O</span>股价盘前大跌59.6%，至64美分 </p><p>** 美国 FDA 拒绝批准 (<span>link</span>) 公司的 Lytenava 用于治疗湿性年龄相关性黄斑变性，理由是缺乏确证疗效的证据</p><p>** 该决定是继 2023 年和 2025 年 8 月拒绝批准后的第三次拒绝。</p><p>** Lytenava是贝伐珠单抗针对眼部疾病的改良药物，在关键试验中未能与罗氏<span>ROG.S</span>的Lucentis相媲美</p><p>** 该药物已在欧盟和英国获得批准；FDA尚未说明可接受哪种类型的确证证据</p><p>** 2025年OTLK下跌16.4 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OTLK","symbol_name":"Outlook Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nL4S3Y30D2:1","article_id":"2600507340","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600507340","pubTimestamp":1767352400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"1月2日 - ** Outlook Therapeutics OTLK.O股价盘前大跌59.6%，至64美分 ** 美国 FDA 拒绝批准  公司的 Lytenava 用于治疗湿性年龄相关性黄斑变性，理由是缺乏确证疗效的证据** 该决定是继 2023 年和 2025 年 8 月拒绝批准后的第三次拒绝。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"OTLK":"Outlook Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BUZZ-Outlook Therapeutics Tumbles on Third FDA Dismissal of Eye Drug Application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTLK":0.9},"content_text":"BUZZ-Outlook Therapeutics 因 FDA 第三次驳回眼科药物申请而暴跌\n1月2日 - ** Outlook Therapeutics OTLK.O股价盘前大跌59.6%，至64美分 ** 美国 FDA 拒绝批准 (link) 公司的 Lytenava 用于治疗湿性年龄相关性黄斑变性，理由是缺乏确证疗效的证据** 该决定是继 2023 年和 2025 年 8 月拒绝批准后的第三次拒绝。** Lytenava是贝伐珠单抗针对眼部疾病的改良药物，在关键试验中未能与罗氏ROG.S的Lucentis相媲美** 该药物已在欧盟和英国获得批准；FDA尚未说明可接受哪种类型的确证证据** 2025年OTLK下跌16.4 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}